Although accumulating clinical findings reveal that VEGF-targeted anti-angiogenic therapies did not benefit all cancer patients, suppression of angiogenesis remains a major focus in the treatment of ovarian cancer and has been suggested as a promising ovarian cancer therapeutic [11]. This evidence concerns the gene VEGFA and ovarian cancer.